Cochrane · systematic review · CD009552
Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease
Cheyne, L, Irvin‐Sellers, MJ, White, J · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 57.1%High 3 · 42.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyTiotropium versus ipratropium for chronic obstructive pulmonary disease
Population: chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and are regarded as having moderate to severe COPD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in baseline trough FEV1 Tiotropium vs ipratropium | no estimate extracted | 2 studies · 1073 participants | Moderate Downgraded: imprecision, inconsistency |
All‐cause serious adverse events Tiotropium vs ipratropium | OR 0.5 [0.34, 0.73] | 2 studies · 1073 participants | High |
Hospital admissions (all‐cause) Tiotropium vs ipratropium | OR 0.34 [0.15, 0.76] | 1 study · 538 participants | Moderate |
Mortality (all‐cause) Tiotropium vs ipratropium | OR 1.39 [0.44, 4.39] | 2 studies · 1073 participants | Moderate Downgraded: imprecision, inconsistency |
Quality of life ( Tiotropium vs ipratropium | no estimate extracted | 1 study · 535 participants | Moderate |
Patients with one or more exacerbations Tiotropium vs ipratropium | OR 0.71 [0.52, 0.95] | 2 studies · 1073 participants | High |
Withdrawals Tiotropium vs ipratropium | OR 0.58 [0.41, 0.83] | 2 studies · 1073 participants | High |
Tiotropium versus ipratropium for chronic obstructive pulmonary disease
Population: chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and are regarded as having moderate to severe COPD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in baseline trough FEV1 Tiotropium vs ipratropium | no estimate extracted | 2 studies · 1073 participants | Moderate Downgraded: imprecision, inconsistency |
All‐cause serious adverse events Tiotropium vs ipratropium | OR 0.5 [0.34, 0.73] | 2 studies · 1073 participants | High |
Hospital admissions (all‐cause) Tiotropium vs ipratropium | OR 0.34 [0.15, 0.76] | 1 study · 538 participants | Moderate |
Mortality (all‐cause) Tiotropium vs ipratropium | OR 1.39 [0.44, 4.39] | 2 studies · 1073 participants | Moderate Downgraded: imprecision, inconsistency |
Quality of life ( Tiotropium vs ipratropium | no estimate extracted | 1 study · 535 participants | Moderate |
Patients with one or more exacerbations Tiotropium vs ipratropium | OR 0.71 [0.52, 0.95] | 2 studies · 1073 participants | High |
Withdrawals Tiotropium vs ipratropium | OR 0.58 [0.41, 0.83] | 2 studies · 1073 participants | High |